🏛️ Verified NIH Record • Updated 2026-05-20
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy (NCT05800600)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Fox Chase Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
Who can join: Review the eligibility criteria below.
Location: Fox Chase Cancer Center — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (267) 838-8380
Email: ryan.romasko@fccc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anemia
- The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females — Huntsville, Alabama
- INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders — Duarte, California
- Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia — Boston, Massachusetts
- INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections — Phoenix, Arizona
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia — Birmingham, Alabama
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Birmingham, Alabama
Explore by condition: All Anemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.